Pulmocide Announces Successful Results from the OPERA-S Study: a Phase 2 Safety Study with Inhaled Opelconazole April 23, 2024
Pulmocide Announces New Clinical Data Confirming Low Potential for Drug-Drug Interactions with Inhaled Opelconazole October 17, 2023
Pulmocide Raises $52 Million to Fund Additional Late-Stage Development of Opelconazole December 7, 2022
Pulmocide’s Lead Drug Candidate Opelconazole (PC945) Granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA September 16, 2021
